• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Robert J. Gray, PhD


  • Dodd LE, Korn EL, Freidlin B, Gu W, Abrams JS, Bushnell WD, Canetta R, Doroshow JH, Gray RJ, Sridhara R.An audit strategy for time-to-event outcomes measured with error: Application to five randomized controlled trials in oncology.Clin Trials. 2013;10(5):754-60.
  • Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S.A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast.Journal of the National Cancer Institute. 2013 May 2.
  • Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW, Sparano JA, Davidson NE, Badve SS.Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.Clin Cancer Res. 2013 Mar 1;19(5):1281-9.
  • Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA.Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: Little evidence of improvement over the past 30 years.Cancer. 2012 Oct 12.
  • Dodd LE, Korn EL, Freidlin B, Gray R, Bhattacharya S.An Audit Strategy for Progression-Free Survival.Biometrics. 2011 Jan 6.
  • Brahmer JR, Dahlberg SE, Gray RJ, Schiller JH, Perry MC, Sandler A, Johnson DH.Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599.J Thorac Oncol. 2011 Jan;6(1):103-8.
  • Wang R, Lagakos SW, Gray RJ.Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring.Biostatistics. 2010 Oct;11(4):676-92.
  • Schroen AT, Petroni GR, Wang H, Gray R, Wang XF, Cronin W, Sargent DJ, Benedetti J, Wickerham DL, Djulbegovic B, Slingluff CL.Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.Clin Trials. 2010 Aug;7(4):312-21.
  • Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, Vaughan WP, Tallman MS, Rebbeck TR, Demichele A.Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.Breast Cancer Res. 2010 May 10;12(3):R26.
  • Freidlin B, Korn EL, Gray R.A general inefficacy interim monitoring rule for randomized clinical trials.Clin Trials. 2010 Jun;7(3):197-208.
  • Bhattacharya S, Fyfe G, Gray RJ, Sargent DJ.Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.J Clin Oncol. 2009 Dec 10;27(35):5958-64.
  • Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL.Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.J Clin Oncol. 2009 Oct 20;27(30):4966-72.
  • Agarwala SS, Gray RJ, Wong MK.Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.J Clin Oncol. 2009 Sep 1;27(25):e82-3; author reply e84.
  • Gray RJ.Weighted analyses for cohort sampling designs.Lifetime Data Analysis. 2009 Mar 31.
  • Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH.Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.J Clin Oncol. 2009 Mar 20;27(9):1405-12.
  • Dahlberg SE,Gray RJ,Johnson BE.Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal.J Clin Oncol. 2008 Sep 10;26(26):4233-5.
  • Ruan PK,Gray RJ.Analyses of cumulative incidence functions via non-parametric multiple imputation.Stat Med. 2008 Nov 29;27(27):5709-24.
  • Gray RJ.Weighted analyses for cohort sampling designs.Lifetime Data Analysis. 2009 Mar;15(1):24-40.
  • Sarojini H, Estrada R, Lu H, Dekova S, Lee MJ, Gray RD, Wang E.PEDF from mouse mesenchymal stem cell secretome attracts fibroblasts.J Cell Biochem. 2008 Aug 1;104(5):1793-802.
  • Freidlin B, Korn EL, Gray R, Martin A.Multi-arm clinical trials of new agents: some design considerations.Clin Cancer Res. 2008 Jul 15;14(14):4368-71. Review.
  • Mekmaysy CS, Petraccone L, Garbett NC, Ragazzon PA, Gray R, Trent JO, Chaires JB.Effect of O(6)-Methylguanine on the Stability of G-Quadruplex DNA.J Am Chem Soc. 2008 May 28;130(21):6710-1.
  • Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH.Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.Clin Cancer Res. 2008 Mar 1;14(5):1407-12.
  • Hughes JH, Mason MC, Gray RJ, McLaughlin SA, Degnim AC, Fulmer JT, Pockaj BA, Karstaedt PJ, Roarke MC.A multi-site validation trial of radioactive seed localization as an alternative to wire localization.Breast J. 2008 Mar-Apr;14(2):153-7.
  • Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH.Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.J Clin Oncol. 2008 Jan 1;26(1):60-5.
  • Lew MW, Falabella A, Moore-Jeffries E, Gray RJ, Sullivan MJ.Oncologic emergencies: the anesthesiologist's perspective.J Natl Compr Canc Netw. 2007 Oct;5(9):860-8.
  • Freidlin B, Korn EL, George SL, Gray R.Randomized clinical trial design for assessing noninferiority when superiority is expected.J Clin Oncol. 2007 Nov 1;25(31):5019-23.
  • Ruan PK, Gray RJ.Sensitivity analysis of progression-free survival with dependent withdrawal.Stat Med. 2008 Apr 15;27(8):1180-98.
  • Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA Jr, Carbone DP.Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.Journal of the National Cancer Institute. 2007 Jun 6;99(11):838-46.
  • Freidlin B, Korn EL, Hunsberger S, Gray R, Saxman S, Zujewski JA.Proposal for the use of progression-free survival in unblinded randomized trials.J Clin Oncol. 2007 May 20;25(15):2122-6.
  • Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA.Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.J Clin Oncol. 2007 May 20;25(15):2127-32.
  • Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med. 2006 Dec 14;355(24):2542-50.
  • Lee ML, Gray RJ, Björkbacka H, Freeman MW.Generalized rank tests for replicated microarray data.Stat Appl Genet Mol Biol. 2005;4(1):Article3.
  • Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, See W, Sweeney C, Liu G, Stein M, Dreicer R, Wilding G, DiPaola RS.Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1966-9. Review.
  • Ruan PK, Gray RJ.A method for analyzing disease-specific mortality with missing cause of death information.Lifetime Data Anal. 2006 Mar;12(1):35-51.
  • Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM.Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.N Engl J Med. 2003 Jul 3;349(1):17-26.
  • Gray RJ, Li Y.Optimal weight functions for marginal proportional hazards analysis of clustered failure time data.Lifetime Data Anal. 2002 Mar;8(1):5-19.
  • Ibrahim JG, Chen M-H, Gray RJ.Bayesian models for gene expression with DNA microarray data.Journal of American Statistical Association. 2002 Mar 01;97:88-99.
  • Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS.Adjuvant therapy for very young women with breast cancer: need for tailored treatments.J Natl Cancer Inst Monogr. 2001(30):44-51.
  • Mutter GL, Baak JP, Fitzgerald JT, Gray R, Neuberg D, Kust GA, Gentleman R, Gullans SR, Wei LJ, Wilcox M.Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation.Gynecol Oncol. 2001 Nov;83(2):177-85.
  • Gray RJ.Estimation of regression parameters and the hazard function in transformed linear survival models.Biometrics. 2000 Jun;56(2):571-6.
  • Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist KW, Pandya KJ, Page DL, Robert NJ.Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189.J Clin Oncol. 2000 May;18(10):2059-69.